Study of the Prevalence and Associated Factors With Hypogonadism in HIV + Men

Completed

• Conditions: Hypogonadism; HIV

• Registration Number: NCT02665559
• Lead Sponsor: Tourcoing Hospital

Brief Summary

Testosterone deficiency is classically associated with the development of metabolic syndrome, osteoporosis, erectile disorder and / or a reduced libido, a depressive syndrome and alteration of the quality of patients life.

Chronicity of HIV infection leads to several disorders as fever, chronic stress, weight loss and cachexia which are the cause of hypogonadotropic hypogonadism. On the other hand, abnormal secretion of cytokines, secondary to the infection may alter the Leydig cells causing a hypergonadotropic hypogonadism and disrupts steroidogenesis. Cases of testicular invasion by lymphoma or Kaposi's syndromes have also been described.

The advent of antiretroviral therapy has reduced the prevalence of hypogonadism in patients infected with HIV that is currently about 20%. This prevalence remains about 20%, regardless of the antiretroviral therapy and CD4-T cell count.

No study to our knowledge has so far assessed exhaustively the clinical features, biological, therapeutic and paraclinical of hypotestosteronemiae while assessing the level of total serum testosterone, SHBG and serum free testosterone, among HIV infected patients in the European population.

Detailed Description

Assess the prevalence and clinical, biological, paraclinical and therapeutic factors associated with primary or secondary hypogonadism in HIV treated and virologically suppressed patients.

Study Timeline

• Study Start: 2013-01
• Study First Submitted: 2013-06-05
• Status Verified: 2016-01
• Study First Submitted QC: 2016-01-26
• Study First Posted: 2016-01-27
• Primary Completion: 2016-06
• Study Completion: 2018-03-31
• Last Update Submitted: 2018-09-14
• Last Update Posted: 2018-09-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 250

Inclusion Criteria

• Men aged 18-50 years at the inclusion visit
• Under antiretroviral treatment for more than six months with undetectable viral load (last sample older than four months before the visit of run)
• Infection by HIV-1 positive (confirmation by a full Western blot or by measurement of plasma HIV RNA prior to the inclusion)
• Lack of co-infections HBV, HCV (last negative serology older than 6 months before the screening visit inclusion)
• Consent signed by the patient and the investigator the day of the inclusion and before any examination required by the test (Article L1122-1-1 the Code of Public Health)
• Patient affiliated or beneficiary of a social security system of the European Community member countries (Article L1121-11 of the Code of Public Health).

Exclusion Criteria

• Infection by HIV-2
• All stages of cirrhosis
• Severe renal impairment (creatinine clearance below 30 ml / min)
• Opportunistic infection during treatment or opportunistic infection in history
• Neoplastic pathology being processed
• Taken in the previous 3 months of testosterone and other anabolic agents, antiandrogens, estrogens, glucocorticoids, analog GnRH, growth hormone or human insulin-like growth factor-1 (IGF-1)
• Pituitary, adrenal or testicular pathologies , treated or not
• Presence or history of psychotic disorder and / or high suicide risk
• Refusal to participate
• No one under safeguard justice
• Patients participating in another research evaluating other treatments and including an exclusion period ongoing at the inclusion

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Testosteron Level	up to 1 year	Quantification of testosteron level at Day 0 of the inclusion and at Day 8 after inclusion

Trial Locations

Locations (1)

Tourcoing Hospital; 🇫🇷 Tourcoing, France